DermRx.

This week

Weekly LLM-curated digest of pipeline moves, readouts, guideline changes, and the prompts that generate them.

Weekly briefAdd data
Last ingest run: 2026-06-14 · 12 new entries from week of 2026-06-08

What's new

Week of 2026-06-08 · 12 changes from ingest

New trials (12)

  • NCT07635043 (PHASE4) — Efficacy of Topical Tapinarof Versus Betamethasone in the Treatment of Plaque Ps
  • NCT07634016 — Global Healthcare Study on Psoriasis
  • NCT07642544 — Effects of Different Secukinumab Maintenance Regimens on Long-Term Outcomes in P
  • NCT07645820 — Evaluation of a Non-Invasive Device for Early Detection of Atopic Dermatitis Fla
  • NCT07643766 (PHASE2) — A Phase 2b Dose-Ranging Study to Evaluate the Efficacy and Safety of ENV-294 in
  • NCT07645430 (NA) — Assessment of Interleukin-15 and Interferon Gamma in Alopecia Areata Before and
  • NCT07637071 (NA) — Study to Evaluate Xtressé Gummy Supplement in Men With Androgenic Alopecia
  • NCT07639073 (PHASE4) — Low-Dose Versus Conventional-Dose Oral Isotretinoin for Acne Vulgaris
  • NCT07637032 (NA) — Clinical Study of a Facial Cream for Rosacea
  • NCT07641686 (NA) — A Study on Scalp Health and Integrated Scalp Management Protocols for Hair Trans
  • NCT07642557 — Remibrutinib in Real-world Clinical Practice - a Germany Sub-study (REASSERT)
  • NCT07632040 (NA) — Pseudoallergen-Free and Low-Histamine Diet in Adolescents With Chronic Spontaneo

Earlier ingest runs

Week of 2026-06-0111 changes · 11 trials

New trials (11)

  • NCT07629778 (PHASE1) — A Phase Ib/II Study of HL-300 Ointment in Patients With Mild-to-Moderate Atopic
  • NCT07618234 (NA) — Dermocosmetic Evaluation of Propolis Ointments in Atopic-Prone Dry Skin
  • NCT07626697 — Dermoscopy and UVFD in Differentiating Palmoplantar Psoriasis and Palmoplantar E
  • NCT07617597 (PHASE3) — Study to Evaluate the Efficacy and Safety of Deuruxolitinib in Japanese Adults W
  • NCT07618195 (PHASE1) — Study of EPI-001 in Patients With Androgenetic Alopecia
  • NCT07626788 (NA) — Pentoxifylline Add-On Therapy for Mild-to-Moderate Plaque Psoriasis
  • NCT07625891 (PHASE2) — A Phase 2 Study of D-2570 in Subjects With Non-Segmental Vitiligo
  • NCT07623486 (PHASE1) — Trial of HSK44459 Cream for the Management Plaque Psoriasis
  • NCT07629336 (PHASE1) — SAR447971 First-in-human Study
  • NCT07620769 (NA) — Safety and Efficacy Evaluation of the Radiofrequency Therapeutic Device for the
  • NCT07620561 (PHASE2) — Efficacy and Speed of Response of Lebrikizumab in High-Burden Prurigo Nodularis
Week of 2026-05-257 changes · 7 trials

New trials (7)

  • NCT07615712 — PPD™ CorEvitas™ Psoriasis (PSO) Rapid Response Non-Interventional Study
  • NCT07611747 (PHASE4) — Carotid Ultrasound-Based Strategy for Primary Prevention of Cardiovascular Event
  • NCT07613190 (NA) — Adjunctive Oral Iron Supplementation in Atopic Dermatitis
  • NCT07615608 (NA) — THERAVEX® REGENERA Tissue Care Plus for Hair Regeneration and Follicular Microen
  • NCT07615257 (NA) — Managing Psychological Distress Through Mindfulness-based CBT to Evaluate Its Ef
  • NCT07606820 (NA) — Real-World Study of Cligabalin(HSK16149) for the Treatment of Neurogenic Rosacea
  • NCT07613866 (PHASE2) — A Clinical Trial of HRS-3095 in Patients With Chronic Spontaneous Urticaria
Week of 2026-05-1813 changes · 13 trials

New trials (13)

  • NCT07594054 — Inflammation Digital Biomarkers Validation Study
  • NCT07598383 (PHASE2) — A Multicenter, Randomized, Double-blind, Vehicle Controlled Phase II Clinical St
  • NCT07604324 (PHASE1) — A First-in-human Study to Investigate Single Doses of DCY636 in Healthy Voluntee
  • NCT07599878 (NA) — Adjunctive Group Psychotherapy for Moderate-to-Severe Atopic Dermatitis: A Pilot
  • NCT07603193 — Real-World Evidence: Effectiveness and Safety of Chronic Hand Eczema Treatment W
  • NCT07599813 (PHASE2) — A Phase 2b Study of the Effects of Camoteskimab in Adults With Moderate-to-Sever
  • NCT07592585 (PHASE3) — Phase III Clinical Study of VC005 in Adult and Adolescents With Mild to Moderate
  • NCT07598058 — PPDTM CorEvitasTM Chronic Hand Eczema (CHE) Drug Safety and Effectiveness Regist
  • NCT07603544 — Multi-Omics Insights Into Androgenetic Alopecia
  • NCT07594678 (PHASE2) — Minoxidil With or Without Low-Level Red-Light Therapy for Improving Chemotherapy
  • NCT07595705 (PHASE2) — Gingival Hyperpigmentation Treatment
  • NCT07595939 (PHASE3) — Efficacy and Safety of Ruxolitinib Cream in Chinese Children Aged 2-11 Years Wit
  • NCT07600424 (NA) — Transcutaneous Auricular Vagus Nerve Stimulation Treatment for Rosacea
Week of 2026-05-1111 changes · 1 approvals · 1 ingredients · 9 trials

New approvals (1)

New ingredients (1)

New trials (9)

  • NCT07580092 — Construct Validity and Responsiveness of EQ-5D-3L and EQ-5D-5L in Patients With
  • NCT07581418 (NA) — Comparison of Methotrexate and Tofacitinib in Chronic Plaque Psoriasis
  • NCT07582783 — A Study of Persistence to Guselkumab Treatment in Participants With Moderate-to-
  • NCT07577921 — Evaluation of the Efficacy of a Cosmetic Care in Subjects With Moderate to Sever
  • NCT07583121 (NA) — Impact of a Daily Application of an Omega-3 Monoglycerides Based Serum and Cream
  • NCT07582237 — Long-Term Follow-up Study of FURESTEM-AD in Patients With Atopic Dermatitis(K010
  • NCT07580911 (NA) — Efficacy and Safety of HA35 Gel for Ultra-Rapid Skin Pruritus Relief
  • NCT07588243 (NA) — A Clinical Study to Evaluate the Efficacy and Safety of Ultra in Promoting Hair
  • NCT07580521 (NA) — Microneedling for Androgenic Alopecia: a Clinical Study
Week of 2026-05-047 changes · 7 trials

New trials (7)

  • NCT07574242 (NA) — Effect of vitk2 on Atopic Dermatitis Pediatrics Patients
  • NCT07568665 — Evaluation by Confocal Reflectance Microscopy of the Skin Structure of Patients
  • NCT07569172 (NA) — Improved Child Nutrition and Development Through Social Transfers
  • NCT07573735 — Assessment of cfDNA-STING Axis as a Potential Pathological Marker in Atopic Derm
  • NCT07572331 (NA) — Clinical Study Evaluating the Safety and Effectiveness of the NIRA Laser M2.1 fo
  • NCT07576023 (NA) — A 4-weeks Comparative Study of Cosmetic Product Versus Standard Medical Care in
  • NCT07567378 — CARTIZ Registry: Cartilage, Arthropathy and Imaging Under Tirzepatide in Zone-st
Week of 2026-04-2714 changes · 14 trials

New trials (14)

  • NCT07552792 (NA) — Impact of Hand Rub Placement on Patient Trust and Disease Stigma
  • NCT07560618 (PHASE4) — Obtaining Descriptive Classifications of Pruritus and Assessing Change in Prurit
  • NCT07559773 (NA) — The ROOT Study: Scaling the 'Standard of Care Plus' Obstetric Nutrition Model to
  • NCT07558668 (PHASE1) — A 3-part Study of SYX-5219 in Healthy Volunteers and Participants With Atopic De
  • NCT07563036 (NA) — JAK2 Expression in Androgenetic Alopecia Before and After Topical Minoxidil
  • NCT07556016 (NA) — Evaluation of the Performance of a Nutricosmetic on Hair & Scalp in Women and Me
  • NCT07557693 (PHASE2) — Mitochondrial Network Modulation Approach Using Hyperbaric Oxygen (HBO) Therapy
  • NCT07552454 (NA) — Picankibart in Palmoplantar Pustulosis
  • NCT07563049 (PHASE4) — Possible Augmentation Of NB-UVB Induced Pigmentation In NSV By Carboxy.
  • NCT07554222 (PHASE1) — Study to Evaluate the Safety, Tolerability and How IBI3013 is Taken up and Proce
  • NCT07556471 (PHASE2) — Evaluation of the Efficacy and Safety of LW402 Tablets in Patients With Non-Segm
  • NCT07554014 (PHASE4) — A Single-center, Prospective, Self-controlled, Observational Real-world Study of
  • NCT07559617 (NA) — Ozonated Oil Emulsion for Seborrhea in Women
  • NCT07557888 — A Prospective, Single-centre, Observational Cohort Study on the Efficacy and Saf
Week of 2026-04-205527 changes · 68 approvals · 33 ingredients · 5422 trials · 4 MOA

New approvals (68)

New trials (5422)

  • NCT00724698 — Evaluation of Desloratadine When Used in Patients With Either Allergic Rhinitis
  • NCT07550452 (NA) — Efficacy and Safety of Switching to Ivarmacitinib in Patients With Moderate-to-S
  • NCT07549750 (PHASE1) — A Dose Escalation Phase 1 Study of HXN5003 in Healthy Participants
  • NCT07549984 (PHASE1) — A Study of IBI3033 in Moderate-to-Severe Atopic Dermatitis
  • NCT07551271 (NA) — Clinical Study of PRP in the Treatment of Androgenetic Alopecia
  • NCT00945373 (PHASE1) — Combination Therapy for the Treatment of Rosacea
  • NCT07549828 (NA) — Sebum Metabolomics and Lipidomics for Clinical Applications
  • NCT04944602 (PHASE3) — Study to Evaluate the Therapeutic Equivalence of SYN008 Versus Xolair® in the Tr
  • NCT05129423 (PHASE2) — A Study of MTPS9579A in Participants With Refractory Chronic Spontaneous Urticar
  • NCT05774639 (PHASE3) — Study to Compare Efficacy Safety and Immunogenicity of ADL-018 With XOLAIR (Omal
  • NCT06295302 (PHASE2) — A Study to Explore the Efficacy and Safety of HWH486 in Adults With Chronic Spon
  • NCT01635127 (PHASE2) — Efficacy Study of Canakinumab to Treat Urticaria
  • NCT07431658 — Effects of Diet and Oxidative Stress on Disease Severity and Response to Omalizu
  • NCT06228560 (PHASE2) — Efficacy and Safety of LP-003 in Patients With CSU Who Remain Symptomatic Despit
  • NCT04538794 (PHASE1) — A Study of CDX-0159 in Patients With Chronic Spontaneous Urticaria
  • NCT04774315 (PHASE4) — Molecular Endotypes of Chronic Idiopathic Urticaria
  • NCT07378527 (PHASE2) — Study of the Efficacy and Safety of ICP-332 in Participants With Chronic Spontan
  • NCT04314999 — Frequency of Parasite Infestation in Patients With Chronic Spontaneous Urticaria
  • NCT07450170 — A Real-World Study of Omalizumab Treatment Patterns in Chronic Urticaria Patient
  • NCT04583475 — Real-life Study of How to Intensify Treatment With Xolair (OMALIZUMAB) in Chroni
  • …and 5402 more

MOA enrichment (4)

Week of 2026-04-131417 changes · 132 approvals · 121 ingredients · 1150 trials · 14 MOA

New approvals (132)

New ingredients (121)

New trials (1150)

  • NCT05103423 (PHASE1) — Safety and Efficacy Study of BDB-001 Injection in Patients With Moderate to Seve
  • NCT05663268 (EARLY_PHASE1) — Efficacy and Safety of Infliximab Biosimilar in the Treatment of Resistant Hidra
  • NCT06028230 (PHASE2) — A Phase 2 Study to Evaluate the Efficacy and Safety of SAR444656 Compared With P
  • NCT03040804 (NA) — Low Dose Radiotherapy for Advanced Hidradenitis Suppurativa
  • NCT06201858 — A Journey Into Participation Patterns Among Patients With Hidradenitis Suppurati
  • NCT06444087 — Patient's Perspective on the Evolution of Hidradenitis Suppurativa Burden After
  • NCT04449354 (NA) — HidraWear Study for Hidradenitis Suppurativa Wounds
  • NCT06368388 — Bacteriophage Therapy for Difficult-to-treat Infections: the Implementation of a
  • NCT05355805 (PHASE2) — Hidradenitis Suppurativa Phase 2b Study of Izokibep
  • NCT02163746 (NA) — Study to Compare Two Treatments for Axillary Hidradenitis Suppurativa: Carbon Di
  • NCT05066113 (NA) — Feasibility Study on Radiofrequency-Based Selective Electrothermolysis to Invest
  • NCT03972280 (PHASE1) — Safety and Pharmacokinetics of Repeat Doses of CSL324 in Subjects With Hidradeni
  • NCT07225569 (PHASE2) — A Study to Investigate Efficacy and Safety With SAR445399 in Adult Participants
  • NCT06895499 (PHASE1) — Efficacy, Safety, and Tolerability of HB0043 in Hidradenitis Suppurativa Patient
  • NCT05020730 (PHASE2) — Trial to Determine the Immunomodulatory Activity of PTM-001 in Patients With Hid
  • NCT05735925 (NA) — The Role of Host-microbiota Interplay in Hidradenitis Suppurativa Pathogenesis
  • NCT05243966 — Myriad™ Augmented Soft Tissue Reconstruction Registry
  • NCT02833909 (NA) — Activation of a Cutaneous Inflammasome in the Skin of Hidradenitis Suppurativa P
  • NCT00367328 (PHASE3) — To Determine the Efficacy of a Laser Device for the Treatment of Hidradenitis Su
  • NCT06707246 (NA) — A Randomized Trial Comparing the Efficacy and Safety of Secukinumab with Tofacit
  • …and 1130 more

MOA enrichment (14)

2026-W16

source: gemini

This weekly brief summarizes key regulatory, clinical, and guideline developments in the fields of psoriasis and atopic dermatitis (AD) for the period of April 1, 2026, to April 17, 2026.

Approvals

Anzupgo (delgocitinib) cream — FDA sNDA Acceptance · April 15, 2026 Source: leo-pharma.com/media-center/news/2026-acceptance-of-anzupgo-snda Why it matters: If approved, this topical pan-JAK inhibitor would be the first indicated treatment specifically for pediatric patients (ages 12–17) with moderate-to-severe chronic hand eczema (CHE).

Icotyde (icotrokinra) — Commercial Launch/Update · April 7, 2026 Source: fda.gov/drugs/novel-drug-approvals-fda/novel-drug-approvals-2026 Why it matters: Following its mid-March approval, new 1-year data confirmed its position as the first targeted oral peptide for IL-23 receptor antagonism, offering biologic-like efficacy in a daily pill for plaque psoriasis.

Trial readouts

Zasocitinib — Phase 3 LATITUDE results (Full Data) · April 7, 2026 Source: clinicaltrials.gov/study/NCT06671483 / hcplive.com/view/6-dermatology-headlines-you-missed-march-2026 Why it matters: Demonstrated superiority over placebo and apremilast in moderate-to-severe psoriasis, with nearly 30% of patients achieving PASI 100 at week 16, reinforcing the strength of the next-gen TYK2 inhibitor pipeline.

Rademikibart — Phase 3 RADIANT-AD 52-week data · April 7, 2026 Source: hcplive.com/view/6-dermatology-headlines-you-missed-march-2026 Why it matters: Long-term data showed sustained near-maximal skin clearance and pruritus control through one year, establishing it as a highly durable IL-4Rα antagonist competitor.

Guideline / safety updates

AAD 2026 Guidelines: Management of Atopic Dermatitis in Pediatric Patients — Publication · April 7, 2026 Source: jaad.org/article/S0190-9622(26)00113-X/fulltext Why it matters: The first pediatric-specific AD guidelines from the AAD, granting "Strong" evidence-based recommendations for aryl hydrocarbon receptor (AhR) agonists like tapinarof in children as young as 2 years old.

International Eczema Council (IEC) Consensus Statement — JAMA Dermatology · April 15, 2026 Source: jamanetwork.com/journals/jamadermatology/fullarticle/2816625 Why it matters: Standardizes the definitions for "Low Disease Activity" and "Remission" in AD, providing essential benchmarks for clinical trial design and "treat-to-target" strategies in routine practice.